Human trials of British coronavirus vaccine to widen to 10,000

6


FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

(Reuters) – Oxford University and AstraZeneca (AZN.L) plan to recruit around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine which on Thursday received U.S. backing worth up to $1.2 billion.

The university said on Friday that partner institutions across Britain had started recruiting up to 10,260 adults and children to see how well the human immune system responds to the vaccine and how safe it is.(bit.ly/2XhETwM)

An initial trial that started on April 23 has already seen more than 1,000 volunteers aged 18-55 receive the injection and Oxford said phases II and III will add people aged 56 and older as well as children of 5 to 12 years.

“The speed at which this new vaccine has advanced into late-stage clinical trials is testament to Oxford’s ground-breaking scientific research,” AstraZeneca executive Mene Pangalos said.

AstraZeneca has already signed up Britain and the United States as partners to mass produce the vaccine in anticipation of confirmation that it works and is safe to use.

Additional reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty and Alexander Smith



feeds.reuters.com 2020-05-22 10:38:28

Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More